SCHEMBL3529137

SCHEMBL3529137

CS(=O)(=O)c1ccccc1N1N=C(C2CC2)CC1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.37
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.36
HTT P42858 1/20 0.36
LOX P28300 1/20 0.35
HSD11B1 P28845 2/20 0.34
MAPT P10636 3/20 0.34
KMT2A Q03164 2/20 0.34
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CHRM2 P08172 1/20 0.34
CYP3A4 P08684 1/20 0.34
CHRM1 P11229 1/20 0.34
TSHR P16473 1/20 0.34
PTGS1 P23219 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3532127 0.80 MAPT (0.45) ALDH1A1SMN1; SMN2LMNAHTTMAPT
SCHEMBL3529723 0.79 SHMT2 (0.43) ALDH1A1SMN1; SMN2LMNATP53LOX
SCHEMBL3537137 0.79 HCAR1 (0.41) ALDH1A1LMNATP53MAPTKMT2A
SCHEMBL3533237 0.77 MEN1 (0.45) ALDH1A1SMN1; SMN2MAPTKMT2AGAA
SCHEMBL3534430 0.77 GAA (0.43) ALDH1A1MAPTKMT2AGAAKDM4E
SCHEMBL3527797 0.75 SLC9A1 (0.40) ALDH1A1SMN1; SMN2LMNAHTTMAPT
SCHEMBL3529246 0.74 ALDH1A1 (0.40) ALDH1A1LMNAHTTHSD11B1MAPT
SCHEMBL3528966 0.73 NOTUM (0.40) DRD2ALDH1A1MAPTKMT2AGAA
SCHEMBL3530839 0.73 GAA (0.57) ALDH1A1SMN1; SMN2LMNAHTTLOX
SCHEMBL3531484 0.71 HCAR1 (0.47) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 DRD2 2741/4885ALDH1A1 105/4885SMN1; SMN2 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.